- Molecular NamePyrazinamide
- SynonymPirazimida; Pirazinamid; Pyrazinamdie; Pyrazine carboxylamide; Pyrazineamide; Pyrazinecarboxamide; Pyrazinecarboxylic acid amide; Pyrazinoic acid amide; PZA
- Weight123.115
- Drugbank_IDDB00339
- ACS_NO98-96-4
- Show 3D model
- LogP (experiment)-0.55
- LogP (predicted, AB/LogP v2.0)-0.68
- pka0.5
- LogD (pH=7, predicted)-0.68
- Solubility (experiment)15.1 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.02
- LogSw (predicted, AB/LogsW2.0)187.12
- Sw (mg/ml) (predicted, ACD/Labs)116.65
- No.of HBond Donors2
- No.of HBond Acceptors4
- No.of Rotatable Bonds1
- TPSA68.87
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug used to treat tuberculosis. The drug is largely bacteriostatic, but can be bacteriocidal on actively replicating tuberculosis bacteria.
- Absorption_value100.0
- Absorption (description)Pyrazinamide is well absorbed orally.
- Caco_2N/A
- Bioavailability90.0
- Protein binding15.0
- Volume of distribution (VD)0.57 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPyrazinamide is hydrolyzed in the liver to an active metabolite, 2-pyrazinoic acid.
- Half life6 h
- ExcretionRenal
- Urinary Excretion4~14
- Clerance1.1 ml/min/kg
- ToxicitySide effects include liver injury, arthralgias, anorexia, nausea and vomiting, dysuria,malaise and fever, sideroblastic anemia, adverse effects on the blood clotting mechanism or vascular integrity, and hypersensitivity reactions such as urticaria, pruritis and skin rashes.
- LD50 (rat)N/A
- LD50 (mouse)N/A